Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Ali Amini Harandi, Shaheed Beheshti Medical University

ClinicalTrials.gov Identifier:

NCT01696123

First received: September 21, 2012

Last updated: September 27, 2012

Last verified: September 2012

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	August 2012
Primary Completion Date:	January 2012 (Final data collection date for primary outcome measure)